Similar articles for PMID: 21507170

Year	Number of Results
2004	2
2005	3
2006	1
2007	5
2008	5
2009	12
2010	7
2011	10
2012	5
2013	4
2014	2
2017	1
2024	0

1

Voriconazole toxicity related to polymorphisms in CYP2C19.

Suan D, O'Connor K, Booth DR, Liddle C, Stewart GJ. Suan D, et al. Intern Med J. 2011 Apr;41(4):364-5. doi: 10.1111/j.1445-5994.2011.02454.x. Intern Med J. 2011. PMID: 21507170 No abstract available.

2

Voriconazole therapeutic drug monitoring: focus on safety.

Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Pasqualotto AC, et al. Expert Opin Drug Saf. 2010 Jan;9(1):125-37. doi: 10.1517/14740330903485637. Expert Opin Drug Saf. 2010. PMID: 20021293 Review.

3

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.

Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Matsumoto K, et al. Int J Antimicrob Agents. 2009 Jul;34(1):91-4. doi: 10.1016/j.ijantimicag.2009.01.008. Epub 2009 Mar 3. Int J Antimicrob Agents. 2009. PMID: 19261446

4

Pharmacogenomics of the triazole antifungal agent voriconazole.

Mikus G, Scholz IM, Weiss J. Mikus G, et al. Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18. Pharmacogenomics. 2011. PMID: 21692616 Review.

5

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D. Hassan A, et al. Ther Drug Monit. 2011 Feb;33(1):86-93. doi: 10.1097/FTD.0b013e31820530cd. Ther Drug Monit. 2011. PMID: 21192313

6

A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.

Lemaitre F, Barbaz M, Scailteux LM, Uhel F, Tadié JM, Verdier MC, Bellissant E. Lemaitre F, et al. Drug Metab Pharmacokinet. 2013;28(5):439-41. doi: 10.2133/dmpk.dmpk-13-nt-007. Epub 2013 Apr 2. Drug Metab Pharmacokinet. 2013. PMID: 23545593 Free article.

7

Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.

Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, Skinner J, Bennett JE. Zonios D, et al. J Infect Dis. 2014 Jun 15;209(12):1941-8. doi: 10.1093/infdis/jiu017. Epub 2014 Jan 7. J Infect Dis. 2014. PMID: 24403552 Free PMC article.

8

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.

Autmizguine J, Krajinovic M, Rousseau J, Théorêt Y, Litalien C, Marquis C, Tapiéro B, Ovetchkine P. Autmizguine J, et al. Pharmacogenomics. 2012 Dec;13(16):1961-5. doi: 10.2217/pgs.12.175. Pharmacogenomics. 2012. PMID: 23215888

9

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. Weiss J, et al. J Clin Pharmacol. 2009 Feb;49(2):196-204. doi: 10.1177/0091270008327537. Epub 2008 Nov 25. J Clin Pharmacol. 2009. PMID: 19033450

10

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning SA, Wilson WH, Walsh TJ. Moriyama B, et al. Mycoses. 2011 Nov;54(6):e877-9. doi: 10.1111/j.1439-0507.2011.02016.x. Epub 2011 May 25. Mycoses. 2011. PMID: 21615537 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

52 results

Results by year